38 daftar pustaka 1. mendis s, puska p, norrving b, world

38

DAFTAR PUSTAKA

1. Mendis S, Puska P, Norrving B, World Health Organization., World Heart

Federation., World Stroke Organization. Global atlas on cardiovascular disease

prevention and control. Geneva: World Health Organization; 2011. vi, 155 p.

p.

2. Yudiarto F, Machfoed M, Darwin A, Ong A, Karyana M, Siswanto. Indonesia

Stroke Registry (S12.003). Neurology. 2014;82(10 Supplement):S12.003.

3. Lamsudin R WS, Nuradyo D, Sutarni S. Stroke Profile in Yogyakarta:

Morbidity, Mortality, and Risk Factor of Stroke. BKM. 1998;Suppl

XIV(Recent Management of Stroke):53-69.

4. Setyopranoto I. Stroke: Gejala dan penatalaksanaan. Cermin Dunia Kedokteran.

2011;38(4):247.

5. Misbach J, Wendra A. Clinical pattern of hospitalized strokes in 28 hospitals

in Indonesia. Medical Journal of Indonesia. 2000;9(1):29-34.

6. Arofah AN. PENATALAKSANAAN STROKE TROMBOTIK: Peluang

Peningkatan Prognosis Pasien. Jurnal Saintika Medika. 2012;7(14).

7. Nurazam M. Analysis of The Time to Hospital Admission for Stroke Patient in

dr Sardjito Hospital from 2011-2013 [Undergraduate Thesis]. Yogyakarta:

Gadjah Mada University; 2014.

8. Muhibbi S. Jumlah Leukosit Sebagai Indikator Keluaran Stroke Iskemik

[Masters Thesis]. Semarang (Indonesia): Universitas Diponegoro; 2004.

9. Dongoran R. Jumlah Neutrofil Absolut sebagai Indikator Keluaran Stroke

Iskemik [Master Thesis]. Semarang (Indonesia): Universitas Diponegoro; 2007.

10. Elkind MSV, Cheng J, Rundek T, Boden-Albala B, Sacco RL. Leukocyte count

predicts outcome after ischemic stroke: The Northern Manhattan Stroke Study.

Journal of Stroke and Cerebrovascular Diseases. 2004;13(5):220-7.

11. Nardi K, Milia P, Eusebi P, Paciaroni M, Caso V, Agnelli G. Admission

Leukocytosis in Acute Cerebral Ischemia: Influence on Early Outcome.

Journal of Stroke and Cerebrovascular Diseases. 2011;21(8):819-24.

39

12. Nomura E, Naka H, Wakabayashi S, Kajikawa H, Matsumoto M. Leukocytes

May Have 2 Opposing Effects in Intravenous rtPA Treatment for Ischemic

Stroke. Clinical and Applied Thrombosis/Hemostasis.

2012:1076029612452115.

13. Tiainen M, Meretoja A, Strbian D, Suvanto J, Curtze S, Lindsberg PJ, et al.

Body temperature, blood infection parameters, and outcome of thrombolysis-

treated ischemic stroke patients. International Journal of Stroke.

2013;8(8):632-8.

14. Furlan JC, Vergouwen MDI, Fang J, Silver FL. White blood cell count is an

independent predictor of outcomes after acute ischaemic stroke. European

Journal of Neurology. 2014;21(2):215-22.

15. Heikinheimo T, Putaala J, Haapaniemi E, Kaste M, Tatlisumak T. Leucocyte

count in young adults with first-ever ischaemic stroke: associated factors and

association on prognosis. International Journal of Stroke. 2015;10(2):245-50.

16. Lipton P. Ischemic cell death in brain neurons. Physiological reviews.

1999;79(4):1431-568.

17. Moskowitz MA, Lo EH, Iadecola C. The Science of Stroke: Mechanisms in

Search of Treatments. Neuron. 2010;67(2):181-98.

18. Jablonska AL, B. Stroke induced brain changes: implications for stem cell

transplantation. Acta Neurobiologiae Experimentalis. 2011.;71(1):74-85.

19. Majid A. Neuroprotection in Stroke: Past, Present, and Future. ISRN

Neurology. 2014;2014:17.

20. Manev H, Favaron M, Guidotti A, Costa E. Delayed increase of Ca2+ influx

elicited by glutamate: role in neuronal death. Molecular pharmacology.

1989;36(1):106-12.

21. Iadecola C, Anrather J. The immunology of stroke: from mechanisms to

translation. Nature medicine. 2011;17(7):796-808.

22. Yilmaz G, Granger DN. Leukocyte recruitment and ischemic brain injury.

Neuromolecular medicine. 2010;12(2):193-204.

40

23. Engelhardt B, Sorokin L. The blood-brain and the blood-cerebrospinal fluid

barriers: function and dysfunction. Seminars in immunopathology.

2009;31(4):497-511.

24. Xu X, Jiang Y. The Yin and Yang of Innate Immunity in Stroke. BioMed

Research International. 2014;2014:8.

25. Jin R, Yang G, Li G. Inflammatory mechanisms in ischemic stroke: role of

inflammatory cells. Journal of leukocyte biology. 2010;87(5):779-89.

26. Hoek RM, Ruuls SR, Murphy CA, Wright GJ, Goddard R, Zurawski SM, et al.

Down-regulation of the macrophage lineage through interaction with OX2

(CD200). Science (New York, NY). 2000;290(5497):1768-71.

27. Cardona AE, Pioro EP, Sasse ME, Kostenko V, Cardona SM, Dijkstra IM, et

al. Control of microglial neurotoxicity by the fractalkine receptor. Nature

neuroscience. 2006;9(7):917-24.

28. Taylor RA, Sansing LH. Microglial responses after ischemic stroke and

intracerebral hemorrhage. Clinical and Developmental Immunology.

2013;2013.

29. Li TP, S; Yu, Y; Wu, X; Guo, J; Zhang, S Proliferation of parenchymal

microglia is the main source of microgliosis after ischaemic stroke. Brain: A

Journal of Neurology. 2013;136(12):3578-88.

30. Chiba T, Umegaki K. Pivotal roles of monocytes/macrophages in stroke.

Mediators of inflammation. 2013;2013.

31. Gelderblom M, Leypoldt F, Steinbach K, Behrens D, Choe C-U, Siler DA, et

al. Temporal and spatial dynamics of cerebral immune cell accumulation in

stroke. Stroke. 2009;40(5):1849-57.

32. Kostulas N, Li H-L, Xiao B-G, Huang Y-M, Kostulas V, Link H. Dendritic

cells are present in ischemic brain after permanent middle cerebral artery

occlusion in the rat. Stroke. 2002;33(4):1129-34.

33. Becker KJ, Kalil AJ, Tanzi P, Zierath DK, Savos AV, Gee JM, et al.

Autoimmune Responses to the Brain After Stroke Are Associated With Worse

Outcome. Stroke. 2011;42(10):2763-9.

41

34. Shibata D, Cain K, Tanzi P, Zierath D, Becker K. Myelin basic protein

autoantibodies, white matter disease and stroke outcome. Journal of

Neuroimmunology. 2012;252(1):106-12.

35. Rocklin RE, Sheremata WA, Feldman RG, Kies MW, David JR. The Guillain-

Barrù Syndrome and Multiple Sclerosis. New England Journal of Medicine.

1971;284(15):803-8.

36. Baird AE, Dambrosia J, Janket S, Eichbaum Q, Chaves C, Silver B, et al. A

three-item scale for the early prediction of stroke recovery. Lancet.

2001;357(9274):2095-9.

37. National Institute of Health Stroke Scale form. Available from:

http://www.ninds.nih.gov/doctors/nih_stroke_scale.pdf.

38. Meisel C, Schwab JM, Prass K, Meisel A, Dirnagl U. Central nervous system

injury-induced immune deficiency syndrome. Nature reviews Neuroscience.

2005;6(10):775-86.

39. Adams HP, Olinger CP, Marler JR, Biller J, Brott TG, Barsan WG, et al.

Comparison of admission serum glucose concentration with neurologic

outcome in acute cerebral infarction. A study in patients given naloxone. Stroke.

1988;19(4):455-8.

40. Young B, Ott L, Dempsey R, Haack D, Tibbs P. Relationship between

admission hyperglycemia and neurologic outcome of severely brain-injured

patients. Annals of Surgery. 1989;210(4):466-73.

41. Nardi K, Milia P, Eusebi P, Paciaroni M, Caso V, Agnelli G. Predictive value

of admission blood glucose level on short-term mortality in acute cerebral

ischemia. Journal of Diabetes and Its Complications. 2012;26(2):70-6.

42. Weir CJ, Murray GD, Dyker AG, Lees KR. Is hyperglycaemia an independent

predictor of poor outcome after acute stroke? Results of a long-term follow up

study. BMJ : British Medical Journal. 1997;314(7090):1303-6.

43. Bruno A, Biller J, Adams HP, Jr., Clarke WR, Woolson RF, Williams LS, et

al. Acute blood glucose level and outcome from ischemic stroke. Trial of ORG

10172 in Acute Stroke Treatment (TOAST) Investigators. Neurology.

1999;52(2):280-4.

http://www.ninds.nih.gov/doctors/nih_stroke_scale.pdf

42

44. Uyttenboogaart M, Koch MW, Stewart RE, Vroomen PC, Luijckx GJ, De

Keyser J. Moderate hyperglycaemia is associated with favourable outcome in

acute lacunar stroke. Brain : a journal of neurology. 2007;130(Pt 6):1626-30.

45. Badiger SA, PT; Narone, U. Hyperglycemia and Stroke. International Journal

of Stroke Research. 2013;1(1):1-6.

46. Thaib P. Hubungan antara kadar LDL darah pada stroke iskemik fase akut

dengan lama perawatan pasien pulang hidup dan pulang meninggal

[Undergraduate Thesis]. Semarang [Indonesia]: Diponegoro University; 2008.

47. Kim E, Tolhurst AT, Qin LY, Chen XY, Febbraio M, Cho S. CD36/fatty acid

translocase, an inflammatory mediator, is involved in hyperlipidemia-induced

exacerbation in ischemic brain injury. The Journal of neuroscience : the official

journal of the Society for Neuroscience. 2008;28(18):4661-70.

48. Putaala J, Strbian D, Mustanoja S, Haapaniemi E, Kaste M, Tatlisumak T.

Functional outcome in young adult ischemic stroke: impact of lipoproteins.

Acta Neurologica Scandinavica. 2013;127(1):61-9.

49. Vauthey C, de Freitas GR, van Melle G, Devuyst G, Bogousslavsky J. Better

outcome after stroke with higher serum cholesterol levels. Neurology.

2000;54(10):1944-9.

50. Roquer J, Cuadrado-Godia E, Rodríguez-Campello A, Jiménez-Conde J,

Martínez-Rodríguez JE, Giralt E, et al. Serum cholesterol levels and survival

after rtPA treatment in acute stroke. European Journal of Neurology.

2012;19(4):648-54.

51. Pikija S, Trkulja V, Juvan L, Ivanec M, Dukši D. Higher on-admission serum

triglycerides predict less severe disability and lower all-cause mortality after

acute ischemic stroke. Journal of Stroke and Cerebrovascular Diseases.

2013;22(7):e15-e24.

52. Leonardi-Bee J, Bath PMW, Phillips SJ, Sandercock PAG, Group ftIC. Blood

Pressure and Clinical Outcomes in the International Stroke Trial. Stroke.

2002;33(5):1315-20.

43

53. Willmot M, Leonardi-Bee J, Bath PMW. High Blood Pressure in Acute Stroke

and Subsequent Outcome: A Systematic Review. Hypertension.

2004;43(1):18-24.

54. Qureshi AI. Acute Hypertensive Response in Patients With Stroke:

Pathophysiology and Management. Circulation. 2008;118(2):176-87.

55. Wardlaw JM, Murray V, Berge E, del Zoppo G, Sandercock P, Lindley RL, et

al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an

updated systematic review and meta-analysis. Lancet. 2012;379(9834):2364-

72.

56. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al. Time

to treatment with intravenous alteplase and outcome in stroke: an updated

pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet.

2010;375(9727):1695-703.

57. Muhammad S, Haasbach E, Kotchourko M, Strigli A, Krenz A, Ridder DA, et

al. Influenza Virus Infection Aggravates Stroke Outcome. Stroke.

2011;42(3):783-91.

58. Aslanyan S, Weir CJ, Diener HC, Kaste M, Lees KR, the GISC, et al.

Pneumonia and urinary tract infection after acute ischaemic stroke: a tertiary

analysis of the GAIN International trial. European Journal of Neurology.

2004;11(1):49-53.

59. Vargas M, Horcajada JP, Obach V, Revilla M, Cervera Á, Torres F, et al.

Clinical Consequences of Infection in Patients With Acute Stroke: Is It Prime

Time for Further Antibiotic Trials? Stroke. 2006;37(2):461-5.

60. Cheng B, Forkert ND, Zavaglia M, Hilgetag CC, Golsari A, Siemonsen S, et

al. Influence of Stroke Infarct Location on Functional Outcome Measured by

the Modified Rankin Scale. Stroke. 2014;45(6):1695-702.

61. Jørgensen HS, Reith J, Pedersen PM, Nakayama H, Olsen TS. Body

temperature and outcome in stroke patients. The Lancet. 1996;348(9021):193.

62. Kammersgaard LP, Jørgensen HS, Rungby JA, Reith J, Nakayama H, Weber

UJ, et al. Admission Body Temperature Predicts Long-Term Mortality After

Acute Stroke: The Copenhagen Stroke Study. Stroke. 2002;33(7):1759-62.

44

63. Wang Y, Lim LL-Y, Levi C, Heller RF, Fisher J. Influence of Admission Body

Temperature on Stroke Mortality. Stroke. 2000;31(2):404-9.

64. Nakayama H, Jørgensen HS, Raaschou HO, Olsen TS. The influence of age on

stroke outcome. The Copenhagen Stroke Study. Stroke. 1994;25(4):808-13.

65. Di Carlo A, Lamassa M, Baldereschi M, Pracucci G, Basile AM, Wolfe CDA,

et al. Sex Differences in the Clinical Presentation, Resource Use, and 3-Month

Outcome of Acute Stroke in Europe: Data From a Multicenter Multinational

Hospital-Based Registry. Stroke. 2003;34(5):1114-9.

66. Glader E-L, Stegmayr B, Norrving B, Terént A, Hulter-Åsberg K, Wester P-O,

et al. Sex Differences in Management and Outcome After Stroke: A Swedish

National Perspective. Stroke. 2003;34(8):1970-5.

67. Wyller TB, Sødring KM, Sveen U, Ljunggren AE, Bautz-Holter E. Are there

gender differences in functional outcome after stroke? Clinical Rehabilitation.

1997;11(2):171-9.

68. Kapral MK, Fang J, Hill MD, Silver F, Richards J, Jaigobin C, et al. Sex

Differences in Stroke Care and Outcomes: Results From the Registry of the

Canadian Stroke Network. Stroke. 2005;36(4):809-14.

69. Courties G, Herisson F, Sager H, Heidt T, Ye Y, Ying W, et al. Ischemic Stroke

Activates Hematopoietic Bone Marrow Stem Cells. Circulation Research. 2014.

70. Buck BH, Liebeskind DS, Saver JL, Bang OY, Yun SW, Starkman S, et al.

Early neutrophilia is associated with volume of ischemic tissue in acute stroke.

Stroke. 2008;39(2):355-60.

71. Nakayama H, Jørgensen H, Raaschou H, Olsen T. The influence of age on

stroke outcome. The Copenhagen Stroke Study. Stroke. 1994;25(4):808-13.

72. Boehme AK, Siegler JE, Mullen MT, Albright KC, Lyerly MJ, Monlezun DJ,

et al. Racial and gender differences in stroke severity, outcomes, and treatment

in patients with acute ischemic stroke. Journal of stroke and cerebrovascular

diseases : the official journal of National Stroke Association. 2014;23(4):e255-

61.

73. Ye JK, Zhang JT, Kong Y, Xu T, Zou TT, Zhang YH, et al. [Relationship

between white blood cell count, neutrophils ratio and erythrocyte

45

sedimentation rate and short clinical outcomes among patients with acute

ischemic stroke at hospital admission]. Zhonghua liu xing bing xue za zhi =

Zhonghua liuxingbingxue zazhi. 2012;33(9):956-60.

46

Lampiran 1. Ethical Clearance

47

Lampiran 2. Surat izin penelitian

48

Lampiran 3. Informed consent

50

Lampiran 4. Spreadsheet data

No Usia Jenis

Kelamin

HDL LDL Kolesterol Trigliserid GDS Jumlah

Leukosit

Skor

NIHSS

Nilai Klinis

NIHSS

1 49 Male 53 131 198 75 155 8.6 2 Defisit Ringan








9 45 Male 43 118 150 100 73 11 11 Defisit Cukup Berat

10 51 Male 35 137 188 91 104 9 6 Defisit Cukup Berat

11 58 Male 38 127 182 76 187 19.6 8 Defisit Cukup Berat

12 70 Male 44 133 199 89 125 7.4 6 Defisit Cukup Berat

13 41 Female 40 99 162 125 175 8.1 3 Defisit Ringan







20 58 Female 21 131 165 91 178 10 14 Defisit Cukup Berat

21 69 Female 57 173 250 114 132 12.5 14 Defisit Cukup Berat

51

Lampiran 5. Output SPSS

Analisis Univariat

Jenis Kelamin

Frequency Percent Valid Percent Cumulative

Percent

Valid

Wanita 9 42.9 42.9 42.9

Pria 12 57.1 57.1 100.0

Total 21 100.0 100.0

Nilai Klinis NIHSS

Frequency Percent Valid Percent Cumulative

Percent

Valid

Defisit Ringan 15 71.4 71.4 71.4

Defisit Cukup Berat 6 28.6 28.6 100.0

Total 21 100.0 100.0

Descriptives

Statistic Std. Error

Usia pasien Mean 57.81 1.747

95% Confidence Interval for Mean Lower Bound 54.17

Upper Bound 61.45

5% Trimmed Mean 58.06

Median 58.00

Variance 64.062

Std. Deviation 8.004

Minimum 41

Maximum 70

Range 29

Interquartile Range 14

Skewness -.281 .501

Kurtosis -.497 .972

Kadar HDL Mean 43.29 3.079


Upper Bound 49.71


52

Median 40.00

Variance 199.114


Minimum 21

Maximum 75

Range 54


Skewness .960 .501

Kurtosis .998 .972

Kadar LDL Mean 135.62 8.716


Upper Bound 153.80


Median 131.00

Variance 1595.448


Minimum 71

Maximum 257

Range 186


Skewness 1.387 .501

Kurtosis 3.348 .972

Kadar Kolesterol Mean 199.81 10.252


Upper Bound 221.20


Median 193.00

Variance 2207.362


Minimum 131

Maximum 308

Range 177


Skewness .689 .501

Kurtosis -.100 .972

Kadar Trigliserida Mean 111.33 9.989


Upper Bound 132.17


Median 100.00

53

Variance 2095.333


Minimum 59

Maximum 265

Range 206


Skewness 2.148 .501

Kurtosis 5.746 .972

Kadar GDS Mean 134.95 10.428


Upper Bound 156.71


Median 125.00

Variance 2283.748


Minimum 73

Maximum 274

Range 201


Skewness 1.202 .501

Kurtosis 2.093 .972

Jumlah Leukosit Mean 9.371 .6678


Upper Bound 10.765


Median 8.600

Variance 9.366


Minimum 6.1

Maximum 19.6

Range 13.5

Interquartile Range 2.6

Skewness 2.076 .501

Kurtosis 5.593 .972

Skor NIHSS Mean 4.43 .893


Upper Bound 6.29


Median 3.00

Variance 16.757

54


Minimum 1

Maximum 14

Range 13


Skewness 1.467 .501

Kurtosis 1.223 .972

Tests of Normality

Kolmogorov-Smirnova Shapiro-Wilk

Statistic df Sig. Statistic df Sig.

Usia pasien .129 21 .200* .965 21 .612

Kadar HDL .242 21 .002 .888 21 .021

Kadar LDL .200 21 .027 .903 21 .040

Kadar Kolesterol .165 21 .139 .948 21 .317

Kadar Trigliserida .204 21 .023 .795 21 .001

Kadar GDS .144 21 .200* .904 21 .043

Jumlah Leukosit .215 21 .012 .806 21 .001

Skor NIHSS .255 21 .001 .783 21 .000

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Analisis Bivariat

T-Test

Group Statistics

gender pasien N Mean Std. Deviation Std. Error Mean

Skor NIHSS Pria 12 4.50 2.876 .830

Wanita 9 4.33 5.523 1.841

55

Independent Samples Test

Levene's Test for Equality of

Variances

t-test for Equality of Means

F Sig. t df Sig. (2-

tailed)

Mean

Difference

Std. Error

Difference

95% Confidence Interval

of the Difference

Lower Upper

Skor

NIHSS

Equal variances

assumed

3.766 .067 1.218 19 .238 .57608 .47308 -.41409 1.56625

Equal variances not

assumed

1.101 10.446 .295 .57608 .52307 -.58268 1.73484

Correlations

Skor

NIHSS

Jumlah

Leukosit

Usia pasien Kadar

GDS

Kadar

HDL

Kadar LDL Kadar

Trigliserid

Kadar

Kolesterol

Skor NIHSS

Pearson

Correlation

1 .460* .066 .190 -.291 -.045 -.149 -.191

Sig. (2-tailed)

.036 .775 .411 .200 .847 .520 .408

N 21 21 21 21 21 21 21 21

Jumlah Leukosit

Pearson

Correlation

.460* 1 -.101 -.104 -.315 -.056 -.072 -.131

Sig. (2-tailed) .036

.663 .652 .164 .809 .756 .572

N 21 21 21 21 21 21 21 21

56

Usia pasien

Pearson

Correlation

.066 -.101 1 .072 .104 .097 .042 .120

Sig. (2-tailed) .775 .663

.758 .653 .676 .857 .603

N 21 21 21 21 21 21 21 21

Kadar GDS

Pearson

Correlation

.190 -.104 .072 1 -.093 .063 -.099 .110

Sig. (2-tailed) .411 .652 .758

.687 .785 .669 .635

N 21 21 21 21 21 21 21 21

Kadar HDL

Pearson

Correlation

-.291 -.315 .104 -.093 1 .530* -.080 .472*

Sig. (2-tailed) .200 .164 .653 .687

.013 .730 .031

N 21 21 21 21 21 21 21 21

Kadar LDL

Pearson

Correlation

-.045 -.056 .097 .063 .530* 1 .301 .902**

Sig. (2-tailed) .847 .809 .676 .785 .013

.184 .000

N 21 21 21 21 21 21 21 21

Kadar Trigliserid

Pearson

Correlation

-.149 -.072 .042 -.099 -.080 .301 1 .380

Sig. (2-tailed) .520 .756 .857 .669 .730 .184

.090

N 21 21 21 21 21 21 21 21

Kadar

Kolesterol

Pearson

Correlation

-.191 -.131 .120 .110 .472* .902** .380 1

Sig. (2-tailed) .408 .572 .603 .635 .031 .000 .090

N 21 21 21 21 21 21 21 21

57

Analisis Multivariat Logistic Regression

Block 0: Beginning Block

Classification Tablea,b

Observed Predicted

Nilai Klinis NIHSS Percentage

Correct .00 1.00

Step 0 Nilai Klinis NIHSS

.00 15 0 100.0

1.00 6 0 .0

Overall Percentage 71.4

a. Constant is included in the model.

b. The cut value is .500

Variables in the Equation

B S.E. Wald df Sig. Exp(B)

Step 0 Constant -.916 .483 3.598 1 .058 .400

Variables not in the Equation

Score df Sig.

Step 0 Variables

VAR00002 .420 1 .517

VAR00003 4.295 1 .038

Overall Statistics 4.308 2 .116

58

Block 1: Method = Backward Stepwise (Likelihood Ratio)

Omnibus Tests of Model Coefficients

Chi-square df Sig.

Step 1

Step 4.575 2 .102

Block 4.575 2 .102

Model 4.575 2 .102

Step 2a

Step -.012 1 .912

Block 4.562 1 .033

Model 4.562 1 .033

a. A negative Chi-squares value indicates that the Chi-

squares value has decreased from the previous step.

Model Summary

Step -2 Log likelihood Cox & Snell R

Square

Nagelkerke R

Square

1 20.553a .196 .281

2 20.565a .195 .280

a. Estimation terminated at iteration number 5 because

parameter estimates changed by less than .001.

Classification Tablea

Observed Predicted

Nilai Klinis NIHSS Percentage

Correct .00 1.00


.00 12 3 80.0

1.00 3 3 50.0



.00 10 5 66.7

1.00 1 5 83.3


a. The cut value is .500

59

Variables in the Equation

B S.E. Wald df Sig. Exp(B)

Step 1a

VAR00002 -.135 1.224 .012 1 .912 .873

VAR00003 2.345 1.285 3.329 1 .068 10.434

Constant -2.291 1.054 4.727 1 .030 .101

Step 2a VAR00003 2.303 1.225 3.535 1 .060 10.000

Constant -2.303 1.049 4.820 1 .028 .100

a. Variable(s) entered on step 1: VAR00002, VAR00003.

Model if Term Removed

Variable Model Log

Likelihood

Change in -2

Log Likelihood

df Sig. of the

Change

Step 1 VAR00002 -10.282 .012 1 .912

VAR00003 -12.362 4.172 1 .041

Step 2 VAR00003 -12.564 4.562 1 .033

Variables not in the Equation

Score df Sig.

Step 2a Variables VAR00002 .012 1 .912

Overall Statistics .012 1 .912

a. Variable(s) removed on step 2: VAR00002.

60

Lampiran 6. Kuesioner penelitian

63

Lampiran 7. Dokumentasi

64

Lampiran 8. Biodata mahasiswa

Identitas

Nama : Yoshua Kevin Poonatajaya

NIM : 22010111120012

Tempat, tanggal lahir : Pati, 2 Oktober 1993

Jenis kelamin : Laki-laki

Alamat : Jl. Kolonel Sunandar 38 Pati

Nomor HP : 081225119904

e-mail : [email protected]

Riwayat Pendidikan Formal

SD : SD Kr. Aletheia Surabaya (Lulus tahun 2005)

SMP : SMP K Keluarga Pati (Lulus tahun 2008)

SMA : SMA N 1 Pati (Lulus tahun 2011)

FK UNDIP : masuk tahun 2011

38 daftar pustaka 1. mendis s, puska p, norrving b, world

Documents